Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GPR3 | P46089 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.38 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.32 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.32 |
| ▸ | GABRP | O00591 | 1/20 | 0.32 |
| ▸ | GABRD | O14764 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13171265 | 0.77 | KDM4E (0.44) | KDM4EGPR3NCEH1ALDH1A1ATM | |
| SCHEMBL22035468 | 0.77 | KDM4E (0.44) | KDM4EGPR3PDE10ATSHRATM | |
| SCHEMBL14533460 | 0.77 | KDM4E (0.44) | KDM4EGPR3PDE10ANCEH1ALDH1A1 | |
| SCHEMBL21871920 | 0.77 | GPR3 (0.44) | KDM4EGPR3PDE10ANCEH1ALDH1A1 | |
| SCHEMBL10272454 | 0.75 | KDM4E (0.42) | KDM4EGPR3PDE10AATMPOLB | |
| SCHEMBL22333840 | 0.72 | DHFR (0.46) | KDM4EGPR3PDE10AALDH1A1SMN1; SMN2 | |
| SCHEMBL14359645 | 0.72 | GCGR (0.42) | KDM4EGPR3PDE10ANCEH1TSHR | |
| SCHEMBL24910164 | 0.71 | KDM4E (0.39) | KDM4EGPR3NCEH1CYP1A2CYP2A6 | |
| SCHEMBL22017076 | 0.71 | KDM4E (0.39) | KDM4EGPR3PDE10AATMPOLB | |
| SCHEMBL5457450 | 0.69 | NCEH1 (0.46) | KDM4ENCEH1TSHRALDH1A1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002412-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. | 2023-01-05 | — | — | US | disclosed |
| US-11161824-B2 | Heterocyclic lipoxin analogs and uses thereof | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2021-11-02 | — | — | US | disclosed |
| US-20210053927-A1 | Heterocyclic Lipoxin Analogs and Uses Thereof | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2021-02-25 | — | — | US | disclosed |
| US-20170290827-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2017-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11161824-B2 | Heterocyclic lipoxin analogs and uses thereof | LTB4R2, ALOX12, ALOX15B | KDM4E 1736/4885GPR3 1175/4885PDE10A 2422/4885 |
| US-20170290827-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | KDM4E 3280/4885GPR3 4121/4885PDE10A 2063/4885 |
| US-20230002412-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | PADI4, PADI2, PADI1 | KDM4E 936/4885GPR3 4415/4885PDE10A 1858/4885 |
| US-20210053927-A1 | Heterocyclic Lipoxin Analogs and Uses Thereof | LTB4R2, ALOX12, ALOX15B | KDM4E 1736/4885GPR3 1175/4885PDE10A 2422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.